 The compelling results of endometriosis treatment MYFEMBREEs phase 3 led to the drugs approval, and Myovant will be eligible for up to 200 million based on achieving certain milestones. The endometriosis market currently has few competitors, and more generally, there are many opportunities in womens health drug development. 